Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

ACR Supports Bill to Establish Minimum DXA Payment

From the College  |  November 21, 2019

Legislation introduced in both houses of Congress would set a minimum Medicare reimbursement of $98 for DXA bone density scans.

Filed under:Legislation & Advocacy Tagged with:bone density testDXA reimbursement cutsFracturesH.R. 2693/S. 238LegislationMedicare

Year in Review: Rheumatic Disease Research in 2019

Thomas R. Collins  |  November 20, 2019

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2019 ACR/ARP Annual MeetingFracturesJAK inhibitorsKnee Osteoarthritis (OA)physical activityPsoriatic ArthritisResearch

High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

Anne Harding  |  September 9, 2019

NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentsteriparatideteriparatide treatment for osteoporosis

Intensive, Personalized Learning

Susan Bernstein  |  August 28, 2019

During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…

Filed under:Education & TrainingProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingEducationeducation and training

Osteoporosis Drugs Don’t Reduce Overall Mortality

Megan Brooks  |  August 21, 2019

NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:FracturesmortalityOsteoporosisosteoporosis treatments

Tanezumab’s Phase 3 Results for OA

Michele B. Kaufman, PharmD, BCGP  |  June 25, 2019

In a recent study, tanezumab proved safe and effective in the treatment of knee and hip osteoarthritis…

Filed under:AnalgesicsDrug Updates Tagged with:hipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Paintanezumab

ACR Pushes for Increased DXA Reimbursement

Linda Childers  |  June 19, 2019

Broken hips are among the most serious injuries incurred by older adults, and many fractures are preventable. According to the Centers for Disease Control and Prevention (CDC), approximately 300,000 people over the age of 65 are hospitalized each year for hip fractures, with women (who have lower bone density than men) experiencing three-quarters of all…

Filed under:Legislation & Advocacy Tagged with:Dr. Chris Phillipsdual-energy X-ray absorptiometry (DXA)DXA reimbursement cutsFractureship fractureIncreasing Access to Osteoporosis Testing for Medicare Beneficiaries Act (S. 283)Ken Saag

U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug

Andrew Chung  |  May 22, 2019

WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…

Filed under:ConditionsDrug UpdatesLegal UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronic acidFosamaxfracture riskFracturesMerck & CoOsteoporosisosteoporosis treatmentsU.S. Supreme Court

Ultrasound Image Review: A 30-Year-Old Woman with Left Foot Pain

Eugene Kissin, MD, RhMSUS, & Catherine Bakewell, MD, RhMSUS  |  May 17, 2019

Presentation A 30-year-old woman presented to her rheumatologist for left foot pain of three weeks’ duration. She was followed for systemic lupus erythematosus manifesting in arthritis and hemolytic anemia, as well as anti-nuclear antibody and Smith antibody positivity, and was treated with hydroxychloroquine and prednisone in the 2.5–10 mg per day range. She was symptom…

Filed under:Conditions Tagged with:FracturesGlucocorticoidsstress fractureUltrasound

ACR Leaders to Meet with Members of Congress

From the College  |  May 2, 2019

On May 16, ACR and ARP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC and Insurance Subcommittee will go to Capitol Hill to advocate on behalf of the College’s membership and our patients. The group represents 31 states and the District of Columbia, and will…

Filed under:ConditionsFrom the CollegeLegislation & AdvocacyOsteoarthritis and Bone DisordersWorkforce Tagged with:Capitol Hill fly-inDepartment of Defense (DoD)Ensuring Seniors’ Timely Access to Care Act of 2019Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act (S. 283)OsteoporosisSafe Step Act of 2019 (H.R. 2279)Strengthening our Pediatric Workforce Act (H.R. 1656)

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences